Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis
Global Pediatric Vaccines Market is expected to cross US$ 40 Billion by the year 2022. Our analysis found that the combination and pneumococcal vaccines was the two leading vaccines segment in 2017 and they continue to dominate the market in future years as well. The market of Combos (Combination vaccines) is thriving as most of the parents believed that if all these vaccines were given separately, than each child would have to take a large number of injections.
By the Year 2022, 500 Million Pediatrics will be get Immunization
Our research found that around 500 million infants get immunization by the year 2022 owing to rising concern against vaccine-preventable diseases and growing awareness. This report covers the past and present scenario and the growth prospects of the infants’ vaccine (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Polio, Haemophilus influenzae type B, Rotavirus, Varicella, Combination) Vaccines market across the world for the period of 2011-2022.
Globally 600 Million Doses of Vaccines will be Administrated in Pediatrics
Our study indicates that that around the globe nearly 600 million doses of vaccines will be administrated in infants by the year 2022 which will be nearly five times the number of influenza doses administered. The number of DTap doses administered in infants is forecast to increase over the years and will cross 50 Million by the year 2022. Report covers detailed information on all the 11 vaccines (Pneumococcal, Rotavirus, Meningococcal, DTap, MMR, Polio, Hepatitis, Varicella, Haemophilus influenzae type B, Influenza, Combination) Vaccines Doses of Vaccines Administered and Forecast.
Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis is the 2nd edition report published by Renub Research on Pediatric Vaccines. This 199 page market research report with 93 Figures and 30 Tables provides data and analysis on Global Pediatric Vaccines Market, Infants Immunized, Number of Vaccine Doses Administered in Pediatric (Infant) (Disease wise) & Key Players.
Vaccine Has Been Extensively Studied From 3 Major Points
1. Global Pediatric (Infant) Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. Pediatric (Infants) Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered in Pediatric (Infant) (Disease wise) & Forecast (2011 – 2022)
11 Vaccines Studied in the Report are as Follows
1. Influenza
2. MMR (Measles, Mumps, and Rubella)
3. Pneumococcal
4. Meningococcal
5. Hepatitis
6. DTap (Diphtheria, Tetanus, Pertussis)
7. Haemophilus influenzae type B
8. Polio
9. Rotavirus
10. Varicella
11. Combination Vaccine
Companies Vaccines Sales and Forecast
1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
5. Others Vaccines
Key Questions Answered In This Report
By the Year 2022, 500 Million Pediatrics will be get Immunization
Our research found that around 500 million infants get immunization by the year 2022 owing to rising concern against vaccine-preventable diseases and growing awareness. This report covers the past and present scenario and the growth prospects of the infants’ vaccine (Influenza, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap, Polio, Haemophilus influenzae type B, Rotavirus, Varicella, Combination) Vaccines market across the world for the period of 2011-2022.
Globally 600 Million Doses of Vaccines will be Administrated in Pediatrics
Our study indicates that that around the globe nearly 600 million doses of vaccines will be administrated in infants by the year 2022 which will be nearly five times the number of influenza doses administered. The number of DTap doses administered in infants is forecast to increase over the years and will cross 50 Million by the year 2022. Report covers detailed information on all the 11 vaccines (Pneumococcal, Rotavirus, Meningococcal, DTap, MMR, Polio, Hepatitis, Varicella, Haemophilus influenzae type B, Influenza, Combination) Vaccines Doses of Vaccines Administered and Forecast.
Pediatric Vaccines Market, Doses, Immunization, Cases and Forecast: Worldwide Analysis is the 2nd edition report published by Renub Research on Pediatric Vaccines. This 199 page market research report with 93 Figures and 30 Tables provides data and analysis on Global Pediatric Vaccines Market, Infants Immunized, Number of Vaccine Doses Administered in Pediatric (Infant) (Disease wise) & Key Players.
Vaccine Has Been Extensively Studied From 3 Major Points
1. Global Pediatric (Infant) Vaccines (Disease wise) Market & Forecast (2011 – 2022)
2. Pediatric (Infants) Immunized (Disease wise) & Forecast (2011 – 2022)
3. Doses of Vaccines Administered in Pediatric (Infant) (Disease wise) & Forecast (2011 – 2022)
11 Vaccines Studied in the Report are as Follows
1. Influenza
2. MMR (Measles, Mumps, and Rubella)
3. Pneumococcal
4. Meningococcal
5. Hepatitis
6. DTap (Diphtheria, Tetanus, Pertussis)
7. Haemophilus influenzae type B
8. Polio
9. Rotavirus
10. Varicella
11. Combination Vaccine
Companies Vaccines Sales and Forecast
1. GlaxoSmithKline, plc Sales & Forecast (2011 – 2022)
2. Merck & Co. Sales & Forecast (2011 – 2022)
3. Sanofi Pasteur’s Sales & Forecast (2011 – 2022)
4. Pfizer, Inc.’s Sales & Forecast (2011 – 2022)
5. Others Vaccines
Key Questions Answered In This Report
- What will be the market size of Global Pediatric Vaccine by the year 2022?
- What are the Key drivers for Pediatric Vaccines Market?
- What are the challenges to Infant Vaccines market?
- Who are the key players in Pediatric Vaccines market?
- What products are in key players Pipeline?
1 RESEARCH FINDINGS
2 GLOBAL - PEDIATRIC (INFANT) VACCINES MARKET AND FORECAST
3 GLOBAL – PEDIATRIC (INFANT) VACCINES MARKET SHARE AND FORECAST
4 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED AND FORECAST
5 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED SHARE AND FORECAST
6 GLOBAL – DOSES OF PEDIATRIC (INFANT) VACCINES ADMINISTERED AND FORECAST
7 GLOBAL – DOSES OF VACCINES ADMINISTERED TO PEDIATRIC (INFANT) SHARE AND FORECAST
8 GLOBAL – VACCINE COMPANIES MARKET SHARE AND FORECAST
9 DISEASE WISE – VACCINES MARKET AND FORECAST
9.1 Influenza – Pediatric (Infant) Vaccines Market and Forecast
9.2 MMR (Measles, Mumps, and Rubella Vaccine) – Pediatric Vaccines Market and Forecast
9.3 Pneumococcal – Pediatric Vaccines Market and Forecast
9.4 Meningococcal – Pediatric Vaccines Market and Forecast
9.5 Hepatitis – Pediatric Vaccines Market and Forecast
9.6 DTaP – Pediatric Vaccines Market and Forecast
9.7 Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast
9.8 Combos (Combination) – Vaccines Market and Forecast
9.9 Polio – Vaccines Market and Forecast
9.1 Rotavirus – Vaccines Market and Forecast
9.11 Varicella – Vaccines Market and Forecast
10 DISEASE WISE – INFANTS IMMUNIZED NUMBERS AND FORECAST
10.1 Influenza – Number of Infants Immunized and Forecast
10.2 MMR – Number of Pediatric (Infants) Immunized and Forecast
10.3 Pneumococcal – Number of Infants Immunized and Forecast
10.4 Meningococcal – Number of Infants Immunized and Forecast
10.5 Hepatitis – Number of Infants Immunized and Forecast
10.6 DTaP – Number of Infants Immunized and Forecast
10.7 Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast
10.8 Combos (Combination Vaccines) – Number of Infants Immunized and Forecast
10.9 Polio – Number of Infants Immunized and Forecast
10.1 Rotavirus – Number of Infants Immunized and Forecast
10.11 Varicella – Number of Infants Immunized and Forecast
11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST
11.1 Influenza – Doses of Infant Vaccines Administered and Forecast
11.2 MMR – Doses of Infant Vaccines Administered and Forecast
11.3 Pneumococcal – Doses of Infant Vaccines Administered and Forecast
11.4 Meningococcal – Doses of Infant Vaccines Administered and Forecast
11.5 Hepatitis – Doses of Infant Vaccines Administered and Forecast
11.6 DTaP – Doses of Infant Vaccines Administered and Forecast
11.7 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
11.8 Polio – Doses of Infant Vaccines Administered and Forecast
11.9 Rotavirus – Doses of Infant Vaccines Administered and Forecast
11.1 Varicella – Doses of Infant Vaccines Administered and Forecast
12 DISEASE WISE - IMMUNIZATION PROFILE
12.1 Immunization Coverage (%) in Infants (2005 – 2015)
12.2 Global Immunization Profile (2011 – 2015)
12.3 Regional Immunization Profile (2001 – 2015)
12.3.1 Measles – Number of Cases Reported
12.3.2 Mumps – Number of Cases Reported
12.3.3 Rubella – Number of Cases Reported
12.3.4 Rubella (CRS) – Number of Cases Reported
12.3.5 Diphtheria – Number of Cases Reported
12.3.6 Tetanus (Neonatal) – Number of Cases Reported
12.3.7 Tetanus (Total) – Number of Cases Reported
12.3.8 Pertussis – Number of Cases Reported
12.3.9 Polio – Number of Cases Reported
12.3.10 Yellow Fever – Number of Cases Reported
12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015
13 VACCINES KEY PLAYERS SALES AND FORECAST
13.1 GlaxoSmithKline, plc.’s Vaccines Sales and Forecast
13.2 Merck & Co. Vaccines Sales and Forecast
13.3 Sanofi Pasteur’s Vaccines Sales and Forecast
13.4 Pfizer, Inc.’s Vaccines Sales and Forecast
13.5 Others Vaccines Sales and Forecast
14 VACCINES – PRODUCTS AND PIPELINE
14.1 GSK Vaccine Product Pipeline
14.2 Merck Vaccine Product Pipeline
14.3 Sanofi Vaccine Product Pipeline
14.4 Pfizer Vaccine Product Pipeline
15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
16 VACCINES AND REGULATOR’S INTERVENTIONS
16.1 Making and Meeting Standards of Quality and Safety
16.2 Vaccine Funding
17 VACCINE MARKET DRIVERS
17.1 Inclusion in National Immunization Schedule
17.2 Growing Immunization Coverage for HPV Vaccines
17.3 Increase in Prevalence of Infectious Diseases
17.4 Global Immunization Vision and Strategy (GIVS)
17.5 GAVI Model Fuelling Vaccine Manufacturers
17.5.1 The Partnership Model
17.5.2 The Business Model
17.6 Increasing Vaccine Availability in United States
17.7 The Vaccine Safety Data link Project
17.8 The Vaccine Injury Compensation Program
17.9 Transforming of Vaccine Technologies
17.1 Global Vaccine Action Plan by WHO (2011 - 2020)
17.11 Continuous Focus on Effective Communication Strategies
18 VACCINES MARKET CHALLENGES
18.1 Hurdles to Optimal use of Licensed Vaccines
18.1.1 Technical Obstacles
18.1.2 Economic Obstacles
18.1.3 Cultural Obstacles
18.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
18.2.1 Legal Obstacles
18.2.2 General Technical Barriers
18.2.3 Economic Barriers
18.2.4 Regulatory Barriers
18.3 Shortening the Timeline for Vaccine Development
18.4 Refusal/Resistance to Vaccination
18.4.1 Vaccine Adverse Event Reporting System
18.5 Vaccine Shortages and Delays
18.6 Obstacles in Vaccine Research & Development
18.7 Barriers to New Entrants in the Vaccines Market
LISTS OF TABLES
Table 3-1: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2016
Table 3-2: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017 - 2022
Table 5-1: Global – Pediatric (Infant) Immunized Share (Percent), 2011 – 2016
Table 5-2: Global – Forecast for Pediatric (Infant) Immunized Share (Percent), 2017 – 2022
Table 7-1: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2016
Table 7-2: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017 - 2022
Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015
Table 12-2: Measles – Number of Cases Reported, 2001 – 2015
Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015
Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015
Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015
Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015
Table 12-10: Polio – Number of Cases Reported, 2001 - 2015
Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015
Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015
Table 14-1: Merck Vaccine Product Pipeline
Table 14-2: Sanofi Vaccine Product Pipeline
Table 14-3: Pfizer Vaccine Product Pipeline
Table 15-1: Vaccine Mergers & Acquisitions
Table 17-1: United States Immunization Schedule
Table 17-2: Afghanistan Immunization Schedule
Table 17-3: Norway Immunization Schedule
Table 17-4: India Immunization Schedule
Table 17-5: Vietnam Immunization Schedule
Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 17-7: Goal-Level Indicators, 2015 & 2020
Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
2 GLOBAL - PEDIATRIC (INFANT) VACCINES MARKET AND FORECAST
3 GLOBAL – PEDIATRIC (INFANT) VACCINES MARKET SHARE AND FORECAST
4 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED AND FORECAST
5 GLOBAL – PEDIATRIC (INFANT) IMMUNIZED SHARE AND FORECAST
6 GLOBAL – DOSES OF PEDIATRIC (INFANT) VACCINES ADMINISTERED AND FORECAST
7 GLOBAL – DOSES OF VACCINES ADMINISTERED TO PEDIATRIC (INFANT) SHARE AND FORECAST
8 GLOBAL – VACCINE COMPANIES MARKET SHARE AND FORECAST
9 DISEASE WISE – VACCINES MARKET AND FORECAST
9.1 Influenza – Pediatric (Infant) Vaccines Market and Forecast
9.2 MMR (Measles, Mumps, and Rubella Vaccine) – Pediatric Vaccines Market and Forecast
9.3 Pneumococcal – Pediatric Vaccines Market and Forecast
9.4 Meningococcal – Pediatric Vaccines Market and Forecast
9.5 Hepatitis – Pediatric Vaccines Market and Forecast
9.6 DTaP – Pediatric Vaccines Market and Forecast
9.7 Haemophilus Influenzae Type B (HIB) – Vaccines Market and Forecast
9.8 Combos (Combination) – Vaccines Market and Forecast
9.9 Polio – Vaccines Market and Forecast
9.1 Rotavirus – Vaccines Market and Forecast
9.11 Varicella – Vaccines Market and Forecast
10 DISEASE WISE – INFANTS IMMUNIZED NUMBERS AND FORECAST
10.1 Influenza – Number of Infants Immunized and Forecast
10.2 MMR – Number of Pediatric (Infants) Immunized and Forecast
10.3 Pneumococcal – Number of Infants Immunized and Forecast
10.4 Meningococcal – Number of Infants Immunized and Forecast
10.5 Hepatitis – Number of Infants Immunized and Forecast
10.6 DTaP – Number of Infants Immunized and Forecast
10.7 Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized and Forecast
10.8 Combos (Combination Vaccines) – Number of Infants Immunized and Forecast
10.9 Polio – Number of Infants Immunized and Forecast
10.1 Rotavirus – Number of Infants Immunized and Forecast
10.11 Varicella – Number of Infants Immunized and Forecast
11 DISEASE WISE – DOSES OF VACCINES ADMINISTERED AND FORECAST
11.1 Influenza – Doses of Infant Vaccines Administered and Forecast
11.2 MMR – Doses of Infant Vaccines Administered and Forecast
11.3 Pneumococcal – Doses of Infant Vaccines Administered and Forecast
11.4 Meningococcal – Doses of Infant Vaccines Administered and Forecast
11.5 Hepatitis – Doses of Infant Vaccines Administered and Forecast
11.6 DTaP – Doses of Infant Vaccines Administered and Forecast
11.7 Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered and Forecast
11.8 Polio – Doses of Infant Vaccines Administered and Forecast
11.9 Rotavirus – Doses of Infant Vaccines Administered and Forecast
11.1 Varicella – Doses of Infant Vaccines Administered and Forecast
12 DISEASE WISE - IMMUNIZATION PROFILE
12.1 Immunization Coverage (%) in Infants (2005 – 2015)
12.2 Global Immunization Profile (2011 – 2015)
12.3 Regional Immunization Profile (2001 – 2015)
12.3.1 Measles – Number of Cases Reported
12.3.2 Mumps – Number of Cases Reported
12.3.3 Rubella – Number of Cases Reported
12.3.4 Rubella (CRS) – Number of Cases Reported
12.3.5 Diphtheria – Number of Cases Reported
12.3.6 Tetanus (Neonatal) – Number of Cases Reported
12.3.7 Tetanus (Total) – Number of Cases Reported
12.3.8 Pertussis – Number of Cases Reported
12.3.9 Polio – Number of Cases Reported
12.3.10 Yellow Fever – Number of Cases Reported
12.3.11 Japanese encephalitis – Number of Cases Reported, 2006 - 2015
13 VACCINES KEY PLAYERS SALES AND FORECAST
13.1 GlaxoSmithKline, plc.’s Vaccines Sales and Forecast
13.2 Merck & Co. Vaccines Sales and Forecast
13.3 Sanofi Pasteur’s Vaccines Sales and Forecast
13.4 Pfizer, Inc.’s Vaccines Sales and Forecast
13.5 Others Vaccines Sales and Forecast
14 VACCINES – PRODUCTS AND PIPELINE
14.1 GSK Vaccine Product Pipeline
14.2 Merck Vaccine Product Pipeline
14.3 Sanofi Vaccine Product Pipeline
14.4 Pfizer Vaccine Product Pipeline
15 TOP MERGERS AND ACQUISITIONS IN THE VACCINE INDUSTRY
16 VACCINES AND REGULATOR’S INTERVENTIONS
16.1 Making and Meeting Standards of Quality and Safety
16.2 Vaccine Funding
17 VACCINE MARKET DRIVERS
17.1 Inclusion in National Immunization Schedule
17.2 Growing Immunization Coverage for HPV Vaccines
17.3 Increase in Prevalence of Infectious Diseases
17.4 Global Immunization Vision and Strategy (GIVS)
17.5 GAVI Model Fuelling Vaccine Manufacturers
17.5.1 The Partnership Model
17.5.2 The Business Model
17.6 Increasing Vaccine Availability in United States
17.7 The Vaccine Safety Data link Project
17.8 The Vaccine Injury Compensation Program
17.9 Transforming of Vaccine Technologies
17.1 Global Vaccine Action Plan by WHO (2011 - 2020)
17.11 Continuous Focus on Effective Communication Strategies
18 VACCINES MARKET CHALLENGES
18.1 Hurdles to Optimal use of Licensed Vaccines
18.1.1 Technical Obstacles
18.1.2 Economic Obstacles
18.1.3 Cultural Obstacles
18.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
18.2.1 Legal Obstacles
18.2.2 General Technical Barriers
18.2.3 Economic Barriers
18.2.4 Regulatory Barriers
18.3 Shortening the Timeline for Vaccine Development
18.4 Refusal/Resistance to Vaccination
18.4.1 Vaccine Adverse Event Reporting System
18.5 Vaccine Shortages and Delays
18.6 Obstacles in Vaccine Research & Development
18.7 Barriers to New Entrants in the Vaccines Market
LISTS OF TABLES
Table 3-1: Global – Pediatric (Infant) Vaccines Market Share (Percent), 2011 - 2016
Table 3-2: Global – Forecast for Pediatric (Infant) Vaccines Market Share (Percent), 2017 - 2022
Table 5-1: Global – Pediatric (Infant) Immunized Share (Percent), 2011 – 2016
Table 5-2: Global – Forecast for Pediatric (Infant) Immunized Share (Percent), 2017 – 2022
Table 7-1: Global – Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2011 - 2016
Table 7-2: Global – Forecast for Doses of Vaccines Administered to Pediatric (Infant) Share (Percent), 2017 - 2022
Table 12-1: Worldwide – Number of Reported Cases, 2011 – 2015
Table 12-2: Measles – Number of Cases Reported, 2001 – 2015
Table 12-3: Mumps – Number of Cases Reported, 2001 - 2015
Table 12-4: Rubella – Number of Cases Reported, 2001 - 2015
Table 12-5: Rubella (CRS) – Number of Cases Reported, 2001 - 2015
Table 12-6: Diphtheria – Number of Cases Reported, 2001 - 2015
Table 12-7: Tetanus (Neonatal) – Number of Cases Reported, 2001 – 2015
Table 12-8: Tetanus (Total) – Number of Cases Reported, 2001 - 2015
Table 12-9: Pertussis – Number of Cases Reported, 2001 - 2015
Table 12-10: Polio – Number of Cases Reported, 2001 - 2015
Table 12-11: Yellow Fever – Number of Cases Reported, 2001 - 2015
Table 12-12: Japanese encephalitis – Number of Cases Reported, 2006 - 2015
Table 14-1: Merck Vaccine Product Pipeline
Table 14-2: Sanofi Vaccine Product Pipeline
Table 14-3: Pfizer Vaccine Product Pipeline
Table 15-1: Vaccine Mergers & Acquisitions
Table 17-1: United States Immunization Schedule
Table 17-2: Afghanistan Immunization Schedule
Table 17-3: Norway Immunization Schedule
Table 17-4: India Immunization Schedule
Table 17-5: Vietnam Immunization Schedule
Table 17-6: Worldwide – Total Future Deaths Averted through Vaccination (Million), 2011 – 2020
Table 17-7: Goal-Level Indicators, 2015 & 2020
Table 17-8: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations
LIST OF FIGURES
Figure 2-1: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2016
Figure 2-2: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 – 2022
Figure 4-1: Global – Pediatric (Infant) Immunized (Million), 2011 - 2016
Figure 4-2: Global – Forecast for Pediatric (Infant) Immunized (Million), 2017 – 2022
Figure 6-1: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2016
Figure 6-2: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017 - 2022
Figure 8-1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2016
Figure 8-2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022
Figure 9-1: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-2: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-3: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2016
Figure 9-4: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-5: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2016
Figure 9-6: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 - 2022
Figure 9-7: Areas with frequent epidemics of meningococcal meningitis
Figure 9-8: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-9: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-10: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-11: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-12: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-13: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-14: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2016
Figure 9-15: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-16: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-17: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-18: Polio – Vaccines Market (Million US$), 2011 - 2016
Figure 9-19: Polio – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population 5 Years of Age, 2013
Figure 9-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
Figure 9-22: Rotavirus – Vaccines Market (Million US$), 2011 - 2016
Figure 9-23: Rotavirus – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-24: Varicella – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-25: Varicella – Forecast for Vaccines Market (Billion US$), 2017 – 2022
Figure 10-1: Influenza – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-2: Influenza – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-3: MMR – Number of Pediatric (Infants) Immunized (Thousand), 2011 - 2016
Figure 10-4: MMR – Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017 - 2022
Figure 10-5: Pneumococcal – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-6: Pneumococcal – Forecast for Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-7: Meningococcal – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-8: Meningococcal – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-9: Hepatitis – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-10: Hepatitis – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-11: DTaP – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-12: DTaP – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-13: Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-14: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-15: Combos (Combination Vaccines) – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-16: Combos (Combination Vaccines) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-17: Polio – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-18: Polio – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-19: Rotavirus – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-20: Rotavirus – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-21: Varicella – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-22: Varicella – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 11-1: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-2: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-3: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-4: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-5: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-6: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-7: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-8: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-9: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-10: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-11: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-12: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-13: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-14: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-15: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-16: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-17: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 – 2016
Figure 11-18: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2017 – 2022
Figure 11-19: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-20: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015
Figure 13-1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-4: Worldwide – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
Figure 13-6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-9: Others Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022
Figure 14-1: GSK Vaccine Product Pipeline
Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-5: US Retail Clinics Expected to Surge by 2017
Figure 2-1: Global – Pediatric (Infant) Vaccines Market (Billion US$), 2011 – 2016
Figure 2-2: Global – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 – 2022
Figure 4-1: Global – Pediatric (Infant) Immunized (Million), 2011 - 2016
Figure 4-2: Global – Forecast for Pediatric (Infant) Immunized (Million), 2017 – 2022
Figure 6-1: Global – Doses of Pediatric (Infant) Vaccines Administered (Million), 2011 - 2016
Figure 6-2: Global – Forecast for Doses of Pediatric (Infant) Vaccines Administered (Million), 2017 - 2022
Figure 8-1: Global – Key Players Vaccines Market Share (Percent), 2011 - 2016
Figure 8-2: Global – Forecast for Key Players Vaccines Market Share (Percent), 2017 - 2022
Figure 9-1: Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-2: Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-3: MMR – Pediatric (Infant) Vaccines Market (Million US$), 2011 – 2016
Figure 9-4: MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-5: Pneumococcal – Pediatric (Infant) Vaccines Market (Billion US$), 2011 - 2016
Figure 9-6: Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Billion US$), 2017 - 2022
Figure 9-7: Areas with frequent epidemics of meningococcal meningitis
Figure 9-8: Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-9: Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-10: Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-11: Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-12: DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2011 - 2016
Figure 9-13: DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2017 - 2022
Figure 9-14: Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2011 - 2016
Figure 9-15: Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-16: Combos (Combination) – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-17: Combos (Combination) – Forecast for Vaccines Market (Billion US$), 2017 - 2022
Figure 9-18: Polio – Vaccines Market (Million US$), 2011 - 2016
Figure 9-19: Polio – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-20: Rotavirus Deaths Under Five Years of Age per 100 000 Population 5 Years of Age, 2013
Figure 9-21: Ten Countries Accounting for Almost Two Thirds of All Deaths, 2013
Figure 9-22: Rotavirus – Vaccines Market (Million US$), 2011 - 2016
Figure 9-23: Rotavirus – Forecast for Vaccines Market (Million US$), 2017 - 2022
Figure 9-24: Varicella – Vaccines Market (Billion US$), 2011 - 2016
Figure 9-25: Varicella – Forecast for Vaccines Market (Billion US$), 2017 – 2022
Figure 10-1: Influenza – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-2: Influenza – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-3: MMR – Number of Pediatric (Infants) Immunized (Thousand), 2011 - 2016
Figure 10-4: MMR – Forecast for Number of Pediatric (Infants) Immunized (Thousand), 2017 - 2022
Figure 10-5: Pneumococcal – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-6: Pneumococcal – Forecast for Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-7: Meningococcal – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-8: Meningococcal – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-9: Hepatitis – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-10: Hepatitis – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-11: DTaP – Number of Infants Immunized (Thousand), 2011 - 2016
Figure 10-12: DTaP – Forecast for Number of Infants Immunized (Thousand), 2017 - 2022
Figure 10-13: Hib (Haemophilus Influenzae Type B) – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-14: Hib (Haemophilus Influenzae Type B) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-15: Combos (Combination Vaccines) – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-16: Combos (Combination Vaccines) – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-17: Polio – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-18: Polio – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-19: Rotavirus – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-20: Rotavirus – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 10-21: Varicella – Number of Infants Immunized (Million), 2011 - 2016
Figure 10-22: Varicella – Forecast for Number of Infants Immunized (Million), 2017 - 2022
Figure 11-1: Influenza – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-2: Influenza – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-3: MMR – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-4: MMR – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-5: Pneumococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-6: Pneumococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-7: Meningococcal – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-8: Meningococcal – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-9: Hepatitis – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-10: Hepatitis – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-11: DTaP – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-12: DTaP – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-13: Hib (Haemophilus Influenzae Type B) – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-14: Hib (Haemophilus Influenzae Type B) – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-15: Polio – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-16: Polio – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 11-17: Rotavirus – Doses of Infant Vaccines Administered (Million), 2011 – 2016
Figure 11-18: Rotavirus – Forecast for Doses of Infant Vaccines Administered (Million), 2017 – 2022
Figure 11-19: Varicella – Doses of Infant Vaccines Administered (Million), 2011 - 2016
Figure 11-20: Varicella – Forecast for Doses of Infant Vaccines Administered (Million), 2017 - 2022
Figure 12-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Figure 12-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2015
Figure 13-1: GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-2: Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-3: Merck & Co. Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-4: Worldwide – Forecast for Merck & Co. Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-5: Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2022
Figure 13-6: Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-7: Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-8: Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2017 - 2022
Figure 13-9: Others Vaccines Sales (Billion US$), 2011 - 2016
Figure 13-10: Forecast for Others Vaccines Sales (Billion US$), 2017 - 2022
Figure 14-1: GSK Vaccine Product Pipeline
Figure 17-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 17-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 17-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 17-5: US Retail Clinics Expected to Surge by 2017
